New World monkey efficacy trials for malaria vaccine development: critical path or detour? (Q47889065)

6 February 2018

title

New World monkey efficacy trials for malaria vaccine development: critical path or detour? (English)

1 reference

6 February 2018

0 references

1 reference

Christian F Ockenhouse

3

object named as

Ockenhouse C

1 reference

6 February 2018

D. Gray Heppner

1

object named as

Heppner DG

1 reference

6 February 2018

author name string

Cummings JF

2

1 reference

6 February 2018

Kester KE

4

1 reference

6 February 2018

Lyon JA

5

1 reference

6 February 2018

Gordon DM

6

1 reference

6 February 2018

publication date

1 September 2001

1 reference

6 February 2018

published in

Trends in Parasitology

1 reference

6 February 2018

volume

17

1 reference

6 February 2018

issue

9

1 reference

6 February 2018

page(s)

419-425

1 reference

6 February 2018

Shotgun DNA microarrays and stage-specific gene expression in Plasmodium falciparum malaria

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

A post-genomic challenge: learning to read patterns of protein synthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Immunization against blood-stage rodent malaria using purified parasite antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Induction of protective immunity against experimental infection with malaria using synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Immunization of owl monkeys with a combination of Plasmodium falciparum asexual blood-stage synthetic peptide antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Evolution of the primate lineage leading to modern humans: phylogenetic and demographic inferences from DNA sequences

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Susceptibility of Panamanian Aotus lemurinus lemurinus to sporozoite-induced Plasmodium falciparum (Santa Lucia) infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

The Santa Lucia strain of Plasmodium falciparum as a model for vaccine studies. I. Development in Aotus lemurinus griseimembra monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Allelic forms of gp195, a major blood-stage antigen of Plasmodium falciparum, are expressed in liver stages

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Expression of the precursor of the major merozoite surface antigens during the hepatic stage of malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Identification of a strain-specific malarial antigen exposed on the surface of Plasmodium falciparum-infected erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Genetic analysis of host-parasite coevolution in human malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Major histocompatibility complex class I genes in primates: co-evolution with pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Major histocompatibility complex class II polymorphisms in primates

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Sequence and diversity of DRB genes of Aotus nancymaae, a primate model for human malaria parasites

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Sequence and diversity of MHC DQA and DQB genes of the owl monkey Aotus nancymaae.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Genetic diversity of HLA-A2: evolutionary and functional significance

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Flow cytometric analysis on reactivity of human T lymphocyte-specific and cytokine-receptor-specific antibodies with peripheral blood mononuclear cells of chimpanzee (Pan troglodytes), rhesus macaque (Macaca mulatta), and squirrel monkey (Saimiri sc

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4922%2801%2902012-8

7 January 2021

10.1016/S1471-4922(01)02012-8

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018